IDH2 and central nervous system cancer: Among the 33 lower‐grade gliomas, 45.5% (15/33) had mutations in both IDH and TERTp, 9.1% (3/33) had mutations in IDH only, 27.3% (9/33) were wild‐type IDH and TERTp, and 18.2% (6/33) had mutations in TERTp only (Figure 1).